Spotify Apple Youtube

The World's Largest Podcast on Fatty Liver Disease

We curate content from our 150+ hour audio library into bite-sized pieces so you can focus on what matters to you.

Get All-Access to all Diabetes registering for a tailored experience. One log-in gives you access to all Diabetes episodes!

Register for a tailored experience
S2-5 - Key Insights from the American Diabetes Association 83rd Scientific Sessions

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

In this episode of Getting Ahead of the Rising Tide, co-hosts Ken Cusi and Roger Green are joined by Eric Johnson (University of North Dakota) and Jay Shubrook (Touro University) in a discussion around takeaways and key insights from the just-concluded American Diabetes Association (ADA) 83rd Scientific Sessions.

In an analysis of the meeting, the group expounds on multiple critical concepts that are immediately applicable to the role of frontline treaters in the effort of preventing, detecting and treating an epidemic of liver disease and to promote holistic metabolic health.

Among the many subjects explored, listeners will learn more about the following major themes:

00:00 Introductions

18:09 First impressions on the ADA meeting

22:22 An update on essential recommendations and guidelines for frontline treaters
Ken and Eric discuss their contributions to an updated guideline, Standards of Care in Diabetes – 2023, with new recommendations for the detection and management of NAFLD/NASH in people with diabetes.

27:44 Why and how to use the FIB-4 test
The group elucidates on the practicality of FIB-4 as a frontline screening tool that not only provides a simple to conduct, noninvasive estimate of scarring in the liver, but also a reasonable predictor of cardiovascular disease. There is cogent description around scoring parameters and how FIB-4 can be seamlessly implemented in otherwise time-restricted visitations.

34:44 Treatments available today
The panelists provide in-depth discussion around treatments like pioglitazone, FGF-21s and GLP-1s as therapeutic options available today that can make major impacts on Fatty Liver disease.

43:27 The imminent future of NASH therapeutics
NASH therapeutic development is on the cusp of bringing liver-directed drug to market. While some anti-obesity medications can contribute a beneficial defatting effect on the liver, treating obesity by itself does not outright resolve fibrogenic burden. It is discussed why there remains a need for more liver-directed drugs and how this issue is being resolved.

58:35 New nomenclature rollout for Fatty Liver disease
During the ADA Scientific Sessions, the European Association for the Study of Liver (EASL) simultaneously held a major meeting for the dissemination of hepatology research. At the EASL meeting it was announced that new nomenclature for Fatty Liver disease will be replacing the previous terminology. Read about the changes here: https://easl.eu/news/new_fatty_liver_disease_nomenclature-2/

Steatotic liver disease (SLD) is the new overarching term replacing nonalcoholic steatohepatitis (NASH). Metabolic dysfunction-associated steatotic liver disease (MASLD) is replacing nonalcoholic fatty liver disease (NAFLD)

If you have questions or comments around the contents of this episode, the ADA Scientific Sessions and EASL Congress meetings, screening and therapeutic guidelines and recommendations, new nomenclature or any of the other numerous topics addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

This podcast series and all episodes are produced under a non-restricted grant from Novo Nordisk. Novo Nordisk has neither influenced nor reviewed the contents of this podcast in any way. This content represents the views of the speakers and does not necessarily represent the views of Novo Nordisk. The content herein is for educational purposes only.

ken-ad-r3
louise-ad-r3

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

jump to episode >

S2-E3 – Why Clinical Care Pathways Matter

In this episode of the Rising Tide series, co-hosts Ken Cusi and Roger Green are joined by KOL in public health, Jeff Lazarus, and physician and associate professor of internal medicine, Jeff Budd. The panelists focus on why clinical care pathways matter and drive the message that primary care plays an integral role in fighting fatty liver.

jump to episode >

S2-E2 – A Deeper Dive Into Fatty Liver, NAFLD, and NASH

In this episode of the Rising Tide series for frontline professionals, the patients themselves and caregivers, co-hosts Ken Cusi and Roger Green are joined by KOL in hepatology, Manal Abdelmalek and KOL in endocrinology, Scott Isaacs for a deeper dive into Fatty Liver, NAFLD and NASH. The group discusses: morbidities and mortalities related to fatty liver disease, paradigm-shifting data, screening for risk stratification, pediatric and adolescent populations, unique key takeaways and much more.

jump to episode >

S2-1 – Combating Swelling NAFLD and NASH Prevalence: Drugs, Diagnostics and Guidelines for the Frontline

In the Season 2 debut of the Rising Tide series for healthcare professionals who treat diabetic patients, the patients themselves and their caregivers, co-hosts Ken Cusi and Roger Green are joined by Mazen Noureddin to talk about prevalence and taking action on the frontlines today. The trio explore emerging NASH drugs, noninvasive testing and guidelines for treating different stages of disease progression.

jump to episode >

S1-E2 — What’s Behind The New AACE Fatty Liver Guidelines?

Drs. Mary Rinella, Zobair Younossi and Diana Barb join co-hosts Dr. Ken Cusi and Roger Green to explore the new AACE Fatty Liver guidelines. Learn about the epidemiology and research behind the guidelines and what they recommend for endocrinologists, primary care physicians and allied health professionals when screening, diagnosing and managing Type 2 Diabetes patients for Fatty Liver disease.

jump to episode >

S1-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that reported, in a prospective random sample of 835 people with a median age of 55, NAFLD prevalence as being 37%, NASH as being 14% and advanced fibrosis as being 6% in a random asymptomatic patients. Among patient with Type 2 Diabetes, NAFLD prevalence was 70% and NASH was 35%.

jump to episode >

S1-E1 – New Podcast: Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

In this Premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors Stephen Harrison, Kathleen Corey and Kay Pepin join co-hosts Dr. Ken Cusi and Roger Green to discuss key issues related to the NAFLD-Diabetes Link, NAFLD-Diabetes Dual Prevalence: very high NAFLD and NASH prevalence in diabetics leads to increased CVD risk and other metabolic issues.

jump to episode >
Stay In Touch
Apple Spotify Youtube

Welcome!

louise-ad-r4_1
ken-ad-r4

Welcome to the world's leading source for Fatty Liver podcasts, with close to 500 episodes and conversations with the world's leading Key Opinion Leaders. Listen, learn, participate.

One-Time Access Here

Register below for one-time access to this episode, or register to the lower right for full site access, tailored content alerts and information on fatty liver disease

louise-ad-r4_1
ken-ad-r4

or gain All-Access!

Skip this lite gate by registering for a tailored experience.
One log-in gives you access to all Diabetes episodes!

Register for a tailored experience

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More